AGTR1 and breast carcinoma: Blockade of AT1 by ARBs, such as losartan or candesartan, was shown to inhibit breast cancer cell proliferation in vitro and breast tumor xenograft growth in mice (Chen et al., 2013), suggesting that AT1 may be an interesting target against breast cancer.